Hu Jianxin, Hu Junfeng, Liu Xiandong, Hu Chao, Li Ming, Han Wei
Department of Medicine, Xijing University, Xi'an, Shaanxi Department of General Surgery, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Medicine (Baltimore). 2017 Oct;96(42):e8310. doi: 10.1097/MD.0000000000008310.
Breast cancer (BC) is considered a systemic disease with a primarily locoregional component. The accumulation of basic researches and clinical studies related to cytokine-induced killer (CIK) cells has confirmed their safety and feasibility in treating BC. By searching the PubMed, Embase, CNKI, and Wanfang databases, we conducted a meta-analysis to assess the efficacy and safety of DC/CIK plus chemotherapy regimen (Exp) compared with chemotherapy (Con) alone regimen for breast carcinoma. Studies were pooled, and the relative risk (RR) and its corresponding 95% confidence interval (CI) were calculated.
Eleven relevant articles were included in this meta-analysis. We observed that complete response (CR) (RR = 1.54, 95% CI: 1.09-2.19, Pheterogeneity = .994, I = 0%), partial response (PR) (RR = 1.33, 95% CI: 1.11-1.59, Pheterogeneity = .802, I = 0%) and overall response rate (ORR) (RR = 1.37, 95% CI: 1.20-1.57, Pheterogeneity = .619, I = 0%) in BC patients treatment with DC/CIK plus chemotherapy regimen was improved than that with chemotherapy alone. There was no difference in the incidence of leukopenia, thrombocytopenia, hair loss, nausea/vomiting, hepatic complications, and neurologic complications in BC patient's treatment with DC/CIK plus chemotherapy regimen and with chemotherapy alone.
Compared to chemotherapy alone, DC/CIK plus chemotherapy treatment significantly increased CR, PR, and ORR; however, there was no difference between the safeties.
DC/CIK plus chemotherapy treatment may be a valuable new option for the treatment of breast carcinoma in women. The present study, therefore, provides valuable information to help physicians make treatment decisions for their patients with BC.
乳腺癌（BC）被认为是一种主要具有局部区域成分的全身性疾病。与细胞因子诱导的杀伤（CIK）细胞相关的基础研究和临床研究的积累已证实其在治疗BC方面的安全性和可行性。通过检索PubMed、Embase、CNKI和万方数据库，我们进行了一项荟萃分析，以评估DC/CIK联合化疗方案（实验组）与单纯化疗（对照组）治疗乳腺癌的疗效和安全性。对研究进行汇总，并计算相对风险（RR）及其相应的95%置信区间（CI）。
本荟萃分析纳入了11篇相关文章。我们观察到，DC/CIK联合化疗方案治疗BC患者的完全缓解（CR）（RR = 1.54，95% CI：1.09 - 2.19，P异质性 = 0.994，I = 0%）、部分缓解（PR）（RR = 1.33，95% CI：1.11 - 1.59，P异质性 = 0.802，I = 0%）和总缓解率（ORR）（RR = 1.37，95% CI：1.20 - 1.57，P异质性 = 0.619，I = 0%）均优于单纯化疗。DC/CIK联合化疗方案和单纯化疗治疗BC患者时，白细胞减少、血小板减少、脱发、恶心/呕吐、肝脏并发症和神经并发症的发生率没有差异。
与单纯化疗相比，DC/CIK联合化疗显著提高了CR、PR和ORR；然而，安全性方面没有差异。
DC/CIK联合化疗可能是治疗女性乳腺癌的一个有价值的新选择。因此，本研究提供了有价值的信息，以帮助医生为BC患者做出治疗决策。
